Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 08.03.2006 CHRIST WATER TECHNOLOGY AG and its subsidiaries were deconsolidated on October 31, 2005 in accordance with international accounting regulations. This means that the "AST - Aqua ...
Ludwigshafen, Germany (ots) - BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN), the world's leading chemical company, today announced that it is commencing a cash tender offer for all of the outstanding shares of common stock of Engelhard Corporation (NYSE: EC) for US$37.00 net per share. BASF's price represents a 23% premium above the December 20, 2005 closing price of Engelhard's ...
Ludwigshafen, Germany (ots) - * BASF Intends To Offer US$37.00 Per Share For a Total of US$4.9 Billion * Acquisition Would Make BASF a Leading Provider in the Global Catalyst Business BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN), the world's leading chemical company, has made an all-cash proposal to acquire all outstanding shares of common stock of Engelhard ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 30.11.2005 Sales: EUR 361.9 million, +1.8% y.o.y. Consolidated BWT Group sales rose in the first nine months of 2005 as against the previous year from EUR 355.3 million to EUR 361.9 million ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 25.11.2005 Graz, 25 November 2005. International Technology Group Andritz AG, Austria received an order from Tracodi, Vietnam for construction of a greenfield mill for producing market pulp from the annual crop kenaf. The order value for Andritz ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 30.09.2005 "The 2005/2006 financial year got off to a positive start for feratel. Consolidated sales increased from TEUR 2,753.7 in the first quarter of the previous year to TEUR 2,812.1 in the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 04.08.2005 BWT - the Best Water Technology Group - can report a satisfactory increase in earnings in the first half of the 2005 financial year. The Aqua Systems Technologies segment (AST) made a ...
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 27.06.2005 Mondsee, 28 June 2005: BWT Aktiengesellschaft, Europe's market leader in the water treatment sector, is planning to spin off its wholly owned subsidiary Christ Water Technology AG ...
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 11.05.2005 BWT - the Best Water Technology Group - has made a good start to the 2005 financial year, achieving a 15 % increase in earnings and continued high levels of sales. Consolidated ...
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried/San Diego, March 25, 2003. The biopharmaceutical company MediGene AG (TechDax30: MDG) will discontinue the development project of a CVLP tumor vaccine against cervical cancer. The data obtained from a clinical phase 1/2 trial with the ...
Giessen, Germany (ots) - Diabetes mellitus and cancer are among the diseases of greatest clinical focus. At the ScheBo Biotech AG Symposium during MEDICA on the occasion of the World Congress of Pathology and Laboratory Medicine (WASPaLM) 2001 two specific diagnostic tools with unique clinical approaches will be ...
Gütersloh (ots) - The Bertelsmann AG Supervisory Board has appointed Hartmut Ostrowski, 43, as a deputy member of the Bertelsmann Executive Board, effective October 1, 2001. Ostrowski is scheduled to become a regular Executive Board member on September 1, 2002. He will then become the successor to Gunter ...
Ad hoc-announcement. The sender is solely responsible for the contents of this announcement. Internet: ...
Ad hoc-announcement. The sender is solely responsible for the contents of this announcement. Internet: ...
